Belzutifan, the first FDA-approved HIF-2α inhibitor, has shown remarkable efficacy in clinical trials, with a 60% reduction in tumor size and a 70% improvement in progression-free survival in patients with VHL-associated RCC (12). This evidence concerns the gene EPAS1 and renal cell carcinoma.